Mahendru Vidhi, Tewari Anurag, Katyal Sunil, Grewal Anju, Singh M Rupinder, Katyal Roohi
Department of Anaesthesiology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
J Anaesthesiol Clin Pharmacol. 2013 Oct;29(4):496-502. doi: 10.4103/0970-9185.119151.
Various adjuvants are being used with local anesthetics for prolongation of intraoperative and postoperative analgesia. Dexmedetomidine, the highly selective 2 adrenergic agonist is a new neuraxial adjuvant gaining popularity.
The study was conducted in prospective, double blind manner. It included 120 American Society of Anesthesiology (ASA) class I and II patients undergoing lower limb surgery under spinal anesthesia after approval from hospital ethics committee with written and informed consent of patients.
The patients were randomly allocated into four groups (30 patients each). Group BS received 12.5 mg hyperbaric bupivacaine with normal saline, group BF received 12.5 mg bupivacaine with 25 g fentanyl, group BC received 12.5 mg of bupivacaine supplemented 30 g clonidine, and group BD received 12.5 mg bupivacaine plus 5 g dexmedetomidine. The onset time to reach peak sensory and motor level, the regression time of sensory and motor block, hemodynamic changes, and side effects were recorded.
Patients in Group BD had significantly longer sensory and motor block times than patients in Groups BC, BF, and BS with Groups BC and BF having comparable duration of sensory and motor block. The mean time of two segment sensory block regression was 147 ± 21 min in Group BD, 117 ± 22 in Group BC, 119 ± 23 in Group BF, and 102 ± 17 in Group BS (P > 0.0001). The regression time of motor block to reach modified Bromage zero (0) was 275 ± 25, 199 ± 26, 196 ± 27, 161 ± 20 in Group BD, BC, BF, and BS, respectively (P > 0.0001). The onset times to reach T8 dermatome and modified Bromage 3 motor block were not significantly different between the groups. Dexmedetomidine group showed significantly less and delayed requirement of rescue analgesic.
Intrathecal dexmedetomidine is associated with prolonged motor and sensory block, hemodynamic stability, and reduced demand of rescue analgesics in 24 h as compared to clonidine, fentanyl, or lone bupivacaine.
多种佐剂正与局部麻醉药联合使用以延长术中和术后镇痛时间。右美托咪定,一种高选择性的α2肾上腺素能激动剂,是一种越来越受欢迎的新型神经轴索佐剂。
本研究以前瞻性、双盲方式进行。研究对象为120例美国麻醉医师协会(ASA)I级和II级患者,经医院伦理委员会批准并获得患者书面知情同意后,接受脊髓麻醉下的下肢手术。
将患者随机分为四组(每组30例)。BS组接受12.5mg重比重布比卡因加生理盐水,BF组接受12.5mg布比卡因加25μg芬太尼,BC组接受12.5mg布比卡因加30μg可乐定,BD组接受12.5mg布比卡因加5μg右美托咪定。记录达到感觉和运动平面峰值的起效时间、感觉和运动阻滞的消退时间、血流动力学变化及副作用。
BD组患者的感觉和运动阻滞时间显著长于BC组、BF组和BS组,BC组和BF组的感觉和运动阻滞持续时间相当。BD组两段感觉阻滞消退的平均时间为(147±21)分钟,BC组为(117±22)分钟,BF组为(119±23)分钟,BS组为(102±17)分钟(P<0.0001)。运动阻滞消退至改良Bromage 0级的时间在BD组、BC组、BF组和BS组分别为(275±25)、(199±26)、(196±27)、(161±20)分钟(P<0.0001)。各组达到T8皮节和改良Bromage 3级运动阻滞的起效时间无显著差异。右美托咪定组的补救镇痛需求显著减少且延迟。
与可乐定、芬太尼或单纯布比卡因相比,鞘内注射右美托咪定可延长运动和感觉阻滞时间,维持血流动力学稳定,并在24小时内减少补救镇痛的需求。